Viewing Study NCT04334759

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:22 PM
Ignite Modification Date: 2026-02-02 @ 9:43 AM
Study NCT ID: NCT04334759
Status: COMPLETED
Last Update Posted: 2025-07-18
First Post: 2020-04-02
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
Sponsor: PrECOG, LLC.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Mesothelioma View
None Pleural Mesothelioma View
None Malignant Pleural Mesothelioma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Unresectable Mesothelioma View
None Durvalumab View
None Anti-Programmed Death-Ligand 1 Antibody View
None Immune Checkpoint Inhibitor View
None Ipilimumab View
None Nivolumab View